• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by PowerUp Acquisition Corp.

    2/26/25 9:20:28 PM ET
    $PWUP
    Blank Checks
    Finance
    Get the next $PWUP alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Aspire Biopharma Holdings, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    738920107

    (CUSIP Number)


    02/17/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    738920107


    1Names of Reporting Persons

    Lance Friedman
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    4,883,375.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    4,883,375.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,883,375.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.98 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  Includes 1,875,886 shares of common stock held by Blackstone Capital Advisors, Inc., 2,344,989 share of common stock held by Cobra Alternative Strategies LLC, and 662,500 shares of common stock held by Thor Special Situations LLC.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Aspire Biopharma Holdings, Inc.
    (b)Address of issuer's principal executive offices:

    194 Candelaro Drive, #233, Humacao, Puerto Rico, 00791
    Item 2. 
    (a)Name of person filing:

    Lance Friedman
    (b)Address or principal business office or, if none, residence:

    25 N Market Street, Suite 205, Jacksonville, Florida 32202
    (c)Citizenship:

    United States
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    738920107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    4,883,375
    (b)Percent of class:

    9.98%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    4,883,375

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    4,883,375

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Lance Friedman
     
    Signature:/s/ Lance Friedman
    Name/Title:Lance Friedman
    Date:02/26/2025
    Get the next $PWUP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PWUP

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PWUP
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by PowerUp Acquisition Corp.

    SCHEDULE 13G - Aspire Biopharma Holdings, Inc. (0001847345) (Subject)

    2/26/25 9:20:28 PM ET
    $PWUP
    Blank Checks
    Finance

    PowerUp Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Changes in Control of Registrant, Leadership Update, Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Change in Shell C

    8-K - Aspire Biopharma Holdings, Inc. (0001847345) (Filer)

    2/21/25 4:59:21 PM ET
    $PWUP
    Blank Checks
    Finance

    PowerUp Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Aspire Biopharma Holdings, Inc. (0001847345) (Filer)

    2/20/25 4:45:33 PM ET
    $PWUP
    Blank Checks
    Finance

    $PWUP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Doshi Mayur Mansukhlal

    3 - PowerUp Acquisition Corp. (0001847345) (Issuer)

    8/28/23 5:00:32 PM ET
    $PWUP
    Blank Checks
    Finance

    SEC Form 3 filed by new insider Wadhwani Avinash R

    3 - PowerUp Acquisition Corp. (0001847345) (Issuer)

    8/28/23 5:00:26 PM ET
    $PWUP
    Blank Checks
    Finance

    SEC Form 3: New insider Ajjarapu Surendra K claimed ownership of 4,317,500 units of Class A Ordinary Shares

    3 - PowerUp Acquisition Corp. (0001847345) (Issuer)

    8/28/23 5:00:39 PM ET
    $PWUP
    Blank Checks
    Finance

    $PWUP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aspire Biopharma, Inc., and PowerUp Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-listed Biopharmaceutical Company Driving Breakthrough Innovations in FDA Approved Drugs, Nutraceuticals and Supplements

    Highlights Transaction Valuation: The transaction values Aspire Biopharma, Inc. at a pre-money equity value of approximately $316 million.Industry-Leading Platform: Aspire is focused on developing a pipeline of products utilizing its novel delivery mechanisms to enhance the efficacy of "do no harm" FDA approved drugs, nutraceuticals and supplements.Innovative Drug Delivery Technology: Aspire's patented and patent-pending delivery system includes components specifically formulated to allow rapid sublingual absorption of drugs directly into the blood stream, thus on first pass, avoiding the gastrointestinal tract and liver, mitigating unwanted toxicity of this critical organ.Growth and

    9/3/24 8:01:00 AM ET
    $PWUP
    Blank Checks
    Finance

    Aspire Biopharma, Inc. Signs Letter of Intent to Create a Publicly Listed, Drug Delivery Company Through a Business Combination with PowerUp Acquisition Corp.

    Humacao, PR and New York, NY, July 31, 2024 (GLOBE NEWSWIRE) -- Aspire Biopharma, Inc. ("Aspire" or the "Company"), a developer of a multi-faceted patent protected disruptive drug delivery mechanism technology, and PowerUp Acquisition Corp. (NASDAQ:PWUP), a Nasdaq Global Market® listed special purpose acquisition company ("PowerUp"), today announced that they have signed a non-binding letter of intent ("LOI") for a potential business combination ("Business Combination"). Under the terms of the LOI, following the consummation of the Business Combination, the combined public company would be listed on a national securities exchange. Aspire Biopharma, Inc. is a privately held, early-stag

    7/31/24 8:01:00 AM ET
    $PWUP
    Blank Checks
    Finance

    PowerUp Acquisition Corp. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

    New York, NY, June 05, 2024 (GLOBE NEWSWIRE) -- PowerUp Acquisition Corp. (the "Company") (NASDAQ:PWUP) announced today that, on June 3, 2024, the Company received a notice (the "Notice") from the Nasdaq Listing Qualifications Department ("Nasdaq") indicating that the Company was not compliant with the timely filing requirement for continued listing under Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule"), which requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission ("SEC"). The Notice indicates that the Company must, no later than August 2, 2024, submit a plan to regain compliance with respect to the filing requirement. Followi

    6/5/24 4:05:00 PM ET
    $PWUP
    Blank Checks
    Finance

    $PWUP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PowerUp Acquisition Corp.

    SC 13G/A - PowerUp Acquisition Corp. (0001847345) (Subject)

    7/30/24 10:56:11 AM ET
    $PWUP
    Blank Checks
    Finance

    SEC Form SC 13G filed by PowerUp Acquisition Corp.

    SC 13G - PowerUp Acquisition Corp. (0001847345) (Subject)

    5/28/24 7:58:56 AM ET
    $PWUP
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by PowerUp Acquisition Corp. (Amendment)

    SC 13G/A - PowerUp Acquisition Corp. (0001847345) (Subject)

    2/14/24 9:33:46 AM ET
    $PWUP
    Blank Checks
    Finance